PRESS RELEASE published on 03/18/2025 at 18:30, 2 months 17 days ago Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een CRO gespecialiseerd in biometrie Oxurion NV kondigt intentie aan om meerderheidsbelang in Franse CRO over te nemen, gespecialiseerd in klinisch databeheer en biometrische analyse. Strategische uitbreiding voor farmaceutische sector Overname CRO Oxurion NV Biometrische Analyse Klinisch Databeheer
BRIEF published on 03/18/2025 at 18:05, 2 months 17 days ago Oxurion annonce des mises à jour de transparence concernant les opportunités spéciales d'Atlas Oxurion Opportunités Spéciales Atlas Notifications De Transparence Titres Avec Droit De Vote Législation Belge
BRIEF published on 03/18/2025 at 18:05, 2 months 17 days ago Oxurion Announces Transparency Updates Regarding Atlas Special Opportunities Atlas Special Opportunities Oxurion Belgian Legislation Transparency Notifications Voting Securities
PRESS RELEASE published on 03/18/2025 at 18:00, 2 months 17 days ago Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities LLC Oxurion NV ontvangt meerdere transparantiekennisgevingen van Atlas Special Opportunities LLC over verkoop van aandelen conform Belgische wetgeving. Lees meer op www.oxurion.com Atlas Special Opportunities LLC Transparantiekennisgevingen Aandelen Oxurion NV Belgische Wetgeving
PRESS RELEASE published on 03/18/2025 at 18:00, 2 months 17 days ago Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Oxurion NV receives transparency notifications from Atlas Special Opportunities, LLC regarding selling of voting securities, crossing thresholds. Developing ophthalmic therapies for retinal disease Atlas Special Opportunities Ophthalmic Therapies Oxurion NV Retinal Disease Transparency Notifications
BRIEF published on 03/04/2025 at 19:05, 3 months ago Oxurion prolonge son accord de financement avec Atlas Obligations Convertibles Capitalisation Boursière Oxurion Opportunités Spéciales Atlas Programme De Financement
BRIEF published on 03/04/2025 at 19:05, 3 months ago Oxurion Extends Financing Agreement With Atlas Convertible Bonds Market Capitalization Atlas Special Opportunities Oxurion Financing Program
PRESS RELEASE published on 03/04/2025 at 19:00, 3 months ago Oxurion verlengt haar financieringsprogramma Oxurion NV verlengt financieringsprogramma en past voorwaarden aan in overeenkomst met Atlas Special Opportunities. Meer informatie beschikbaar op oxurion.com Atlas Special Opportunities Oxurion NV Financieringsprogramma Biofarmaceutisch Bedrijf Obligatie
PRESS RELEASE published on 03/04/2025 at 19:00, 3 months ago Oxurion Extends Its Financing Program Oxurion NV signs third amendment to convertible bond subscription agreement with Atlas Special Opportunities II, LLC, extending issuance period and clarifying maturity terms Amendment Convertible Bond Oxurion NV Atlas Special Opportunities II Financing Terms
BRIEF published on 02/14/2025 at 19:05, 3 months 18 days ago Oxurion Enhances Board with Nelly Souleymane's Appointment Innovation Board Changes Biopharmaceutical Diversity Oxurion
Published on 06/05/2025 at 15:00, 13 minutes ago Grande Portage Announces Upsize of Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 06/05/2025 at 15:00, 13 minutes ago Vox Royalty Provides Development Updates Including Initial Construction Earthworks at the Sulphur Springs Copper Project in Australia
Published on 06/05/2025 at 15:00, 13 minutes ago Spetz Inc. Acquires 3.35m Sonic Tokens in First Week as Strategic Accumulation Program Commences
Published on 06/05/2025 at 15:00, 13 minutes ago New to The Street's Client Roadzen (NASDAQ: RDZN) Partners with Vodafone Automotive
Published on 06/05/2025 at 14:30, 43 minutes ago Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Published on 06/05/2025 at 15:00, 13 minutes ago Mynaric Advances Laser Communications with Product Deliveries and Technology Milestones
Published on 06/05/2025 at 14:00, 1 hour 13 minutes ago ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt Disease
Published on 06/05/2025 at 13:57, 1 hour 16 minutes ago naoo AG Launches New App Version with Major Performance Boost and Additional Features
Published on 06/05/2025 at 13:55, 1 hour 18 minutes ago INDUS adds U.S. fabrication and engineering expertise through strategic acquisition
Published on 06/05/2025 at 13:38, 1 hour 35 minutes ago Dalata Hotel Group PLC: HOL-Holding(s) in Company*
Published on 06/05/2025 at 10:04, 5 hours 9 minutes ago LNA Santé : Répartition de capital et des droits de vote attachés aux actions au 31/05/2025
Published on 06/05/2025 at 09:58, 5 hours 15 minutes ago Déclaration du nombre d’actions et droits de vote au 31 mai 2025
Published on 06/05/2025 at 09:58, 5 hours 15 minutes ago Disclosure of Share Capital and Voting Rights as of May 31, 2025
Published on 06/04/2025 at 18:05, 21 hours 8 minutes ago Déclaration nombre d'actions et droits de vote - 04.06.2025
Published on 06/04/2025 at 18:05, 21 hours 8 minutes ago Disclosure of shares outstanding and voting rights - 04.06.2025
